AGN Allergan plc

139.53
-0.78  -1%
Previous Close 140.31
Open 139.46
Price To Book 0.71
Market Cap 46075365120
Shares 330,218,341
Volume 464,458
Short Ratio 1.38
Av. Daily Volume 2,360,512

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval (third indication) announced October 3, 2017.
Botox
Forehead lines
Phase 2 data due 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Approval announced March 20, 2017.
JUVÉDERM VOLLURE
Correction of moderate to severe facial wrinkles and folds
Phase 3 data due 2020.
Brazikumab
Crohn's disease
Phase 3 enrollment to be completed 2H 2018.
Bimatoprost
Androgenic Alopecia
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Botox
Depression
Phase 2b trial ongoing.
RORγt agonist
Psoriasis
Approval announced November 13, 2017.
Cariprazine
Maintenance Treatment of Schizophrenia
Phase 3 data released January 24, 2019 - primary endpoint met.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3 trial to be initiated 1H 2019 with data due in 2020.
ATOGEPANT
Prophylaxis (migraine)
Phase 3 trials did not meet primary endpoints - March 6, 2019.
RAPASTINEL
Major depressive disorder (MDD)
Phase 3 initiated 2H 2017 with top-line data due 2020.
RELAMORELIN
Diabetic Gastroparesis
CRL issued August 21, 2018.
ESMYA (ulipristal acetate)
Uterine Fibroids
Phase 3 trial to be initiated 2019.
ABICIPAR
Diabetic macular edema (DME)
Phase 3 data due 2020.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
Phase 3 data released July 19, 2018. Primary endpoint met. BLA filing due 1H 2019.
ABICIPAR
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
PDUFA date for sNDA filing May 2019.
Cariprazine
Bipolar I Depression
NDA acceptance announced March 11, 2019. PDUFA 4Q 2019. No exact date provided.
UBROGEPANT
Migraine
Phase 2/3 data due 2020.
Brazikumab
Ulcerative colitis
Phase 3 trial to be initiated 2H 2018.
Brimo DDS
Geographic atrophy
NDA filing due 2H 2019.
Bimatoprost
Open-angle glaucoma or ocular hypertension
FDA Approval announced March 18, 2019.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI) - pediatric
PDUFA date 4Q 2019.
Botox
Lower limb spasticity
PDUFA date under priority review 2Q 2019. Exact date not provided.
Botox
Upper limb spasticity

Latest News

  1. Jerome Dodson Goes 2 for 2 in 1st Quarter
  2. Here's What We Think About Allergan plc's (NYSE:AGN) CEO Pay
  3. 50 Top Stocks That Billionaires Love
  4. Gilead Collaborates With Insitro to Develop NASH Therapies
  5. Allergan Falls as Supreme Court Dismisses Restasis Litigation
  6. Could This Backing Help Allergan's CEO Retain His Chairman Role?
  7. Proxy firms back Allergan in fight against Appaloosa
  8. New Study Showcases Economic and Community Impact of Allergan's Operations in Ohio
  9. U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents
  10. Leading Proxy Advisory Firms ISS and Glass Lewis Support ALL of Allergan Board's Voting Recommendations
  11. Alkermes Reports Positive Data From Schizophrenia Study
  12. Allergan Earns 2019 ENERGY STAR® Partner of the Year - Sustained Excellence Award for the Sixth Consecutive Year
  13. These 3 Value Stocks Are Absurdly Cheap Right Now
  14. Wynn ends A$10 billion acquisition talks with Australia's Crown Resorts
  15. Allergan to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast
  16. Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World
  17. Will Ironwood Suffer From Dependence on Linzess' Progress?
  18. Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU